Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Molecular basis of Pirh2-mediated p53 ubiquitylation.

Sheng Y, Laister RC, Lemak A, Wu B, Tai E, Duan S, Lukin J, Sunnerhagen M, Srisailam S, Karra M, Benchimol S, Arrowsmith CH.

Nat Struct Mol Biol. 2008 Dec;15(12):1334-42. doi: 10.1038/nsmb.1521. Epub 2008 Nov 30.

2.

CARPs are E3 ligases that target apical caspases and p53.

Yang W, El-Deiry WS.

Cancer Biol Ther. 2007 Nov;6(11):1676-83. Epub 2007 Aug 24. Review.

PMID:
17986872
3.

PLAGL2 controls the stability of Pirh2, an E3 ubiquitin ligase for p53.

Zheng G, Ning J, Yang YC.

Biochem Biophys Res Commun. 2007 Dec 14;364(2):344-50. Epub 2007 Oct 11.

4.

Ubiquitination and degradation of mutant p53.

Lukashchuk N, Vousden KH.

Mol Cell Biol. 2007 Dec;27(23):8284-95. Epub 2007 Oct 1.

5.

RING domain-mediated interaction is a requirement for MDM2's E3 ligase activity.

Kawai H, Lopez-Pajares V, Kim MM, Wiederschain D, Yuan ZM.

Cancer Res. 2007 Jul 1;67(13):6026-30.

6.
7.

Hetero-oligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2.

Singh RK, Iyappan S, Scheffner M.

J Biol Chem. 2007 Apr 13;282(15):10901-7. Epub 2007 Feb 14.

8.

Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'.

Yamasaki S, Yagishita N, Sasaki T, Nakazawa M, Kato Y, Yamadera T, Bae E, Toriyama S, Ikeda R, Zhang L, Fujitani K, Yoo E, Tsuchimochi K, Ohta T, Araya N, Fujita H, Aratani S, Eguchi K, Komiya S, Maruyama I, Higashi N, Sato M, Senoo H, Ochi T, Yokoyama S, Amano T, Kim J, Gay S, Fukamizu A, Nishioka K, Tanaka K, Nakajima T.

EMBO J. 2007 Jan 10;26(1):113-22. Epub 2006 Dec 14.

9.

Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.

Lindström MS, Jin A, Deisenroth C, White Wolf G, Zhang Y.

Mol Cell Biol. 2007 Feb;27(3):1056-68. Epub 2006 Nov 20.

11.

Solution structure of the Hdm2 C2H2C4 RING, a domain critical for ubiquitination of p53.

Kostic M, Matt T, Martinez-Yamout MA, Dyson HJ, Wright PE.

J Mol Biol. 2006 Oct 20;363(2):433-50. Epub 2006 Aug 14.

PMID:
16965791
12.

Human PIRH2 enhances androgen receptor signaling through inhibition of histone deacetylase 1 and is overexpressed in prostate cancer.

Logan IR, Gaughan L, McCracken SR, Sapountzi V, Leung HY, Robson CN.

Mol Cell Biol. 2006 Sep;26(17):6502-10.

13.

Dual-site regulation of MDM2 E3-ubiquitin ligase activity.

Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL.

Mol Cell. 2006 Jul 21;23(2):251-63.

14.

Structure and E3-ligase activity of the Ring-Ring complex of polycomb proteins Bmi1 and Ring1b.

Buchwald G, van der Stoop P, Weichenrieder O, Perrakis A, van Lohuizen M, Sixma TK.

EMBO J. 2006 Jun 7;25(11):2465-74. Epub 2006 May 18.

15.

The complexity of p53 stabilization and activation.

Lavin MF, Gueven N.

Cell Death Differ. 2006 Jun;13(6):941-50. Review.

16.

The P53 pathway: what questions remain to be explored?

Levine AJ, Hu W, Feng Z.

Cell Death Differ. 2006 Jun;13(6):1027-36. Review.

17.

p53 ubiquitination: Mdm2 and beyond.

Brooks CL, Gu W.

Mol Cell. 2006 Feb 3;21(3):307-15. Review.

18.

Improvement in the accuracy of multiple sequence alignment program MAFFT.

Katoh K, Kuma K, Miyata T, Toh H.

Genome Inform. 2005;16(1):22-33.

PMID:
16362903
19.

ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Chen D, Kon N, Li M, Zhang W, Qin J, Gu W.

Cell. 2005 Jul 1;121(7):1071-83.

20.

Silencers regulate both constitutive and alternative splicing events in mammals.

Pozzoli U, Sironi M.

Cell Mol Life Sci. 2005 Jul;62(14):1579-604. Review.

PMID:
15905961

Supplemental Content

Support Center